Cubist Systematic Strategies LLC Invests $2.34 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Cubist Systematic Strategies LLC purchased a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 124,025 shares of the company's stock, valued at approximately $2,337,000. Cubist Systematic Strategies LLC owned approximately 0.16% of Nurix Therapeutics at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Barclays PLC lifted its position in Nurix Therapeutics by 77.9% during the third quarter. Barclays PLC now owns 128,344 shares of the company's stock valued at $2,884,000 after acquiring an additional 56,190 shares during the last quarter. Franklin Resources Inc. lifted its position in Nurix Therapeutics by 52.4% during the third quarter. Franklin Resources Inc. now owns 123,101 shares of the company's stock valued at $2,766,000 after acquiring an additional 42,315 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Nurix Therapeutics by 85.2% during the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock valued at $1,531,000 after acquiring an additional 31,352 shares during the last quarter. SG Americas Securities LLC lifted its position in Nurix Therapeutics by 31.1% during the fourth quarter. SG Americas Securities LLC now owns 30,086 shares of the company's stock valued at $567,000 after acquiring an additional 7,141 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Nurix Therapeutics by 21.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company's stock valued at $283,000 after acquiring an additional 2,632 shares during the last quarter.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX opened at $9.50 on Monday. The company's fifty day moving average price is $11.49 and its 200 day moving average price is $17.35. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56. The company has a market capitalization of $724.24 million, a PE ratio of -3.29 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The company had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter in the prior year, the firm posted ($0.76) EPS. On average, equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insiders Place Their Bets

In other news, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the sale, the insider now owns 61,516 shares in the company, valued at $707,434. This trade represents a 5.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the sale, the chief financial officer now owns 33,724 shares in the company, valued at approximately $488,660.76. This trade represents a 14.73% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,838 shares of company stock worth $221,500. 7.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on NRIX shares. Stephens reissued an "overweight" rating and issued a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Needham & Company LLC reissued a "buy" rating and issued a $27.00 price target on shares of Nurix Therapeutics in a report on Tuesday, April 29th. JPMorgan Chase & Co. lowered their price target on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Wells Fargo & Company lowered their price target on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, April 9th. Finally, Morgan Stanley boosted their price objective on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a report on Monday, February 3rd. Three investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Nurix Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.44.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.